Salvage chemotherapy plays a central role in the management of patients with relapsed rhabdomyosarcoma. CEV/IVE and VI(T) regimens can be recommended as neoadjuvant chemotherapy before local treatment for patients with relapsed rhabdomyosarcoma.
No takes yet. Share an insight, caveat, or question.
Winter et al. (2015) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: